Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.

Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB

Diabetes care14 Jun 2018Cited by 84 (Europe PMC)

PMID29903847DOI10.2337/dc17-2677PepBankPUB-29903847

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and high cardiovascular risk, severe hypoglycaemia occurred less often with liraglutide than with placebo (rate ratio 0.69).
In plain wordsIn adults with type 2 diabetes and high heart risk, serious low blood sugar happened less often with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
DecreaseSevere hypoglycaemia
Study
n = 9,340
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 3.5-5 yearsAs given in this study (human).
Measurements
Rate ratio
0.69 ratio
severe hypoglycaemia, 95% CI 0.51-0.93
Source sentences
Summary
A total of 267 patients experienced severe hypoglycemia (liraglutide n = 114, placebo n = 153; rate ratio 0.69; 95% CI 0.51, 0.93).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with type 2 diabetes and high risk for CV disease (n = 9,340) were randomized 1:1 to liraglutide or placebo, both in addition to standard treatment, and followed for 3.5-5 years.
Report a problemFND-2990384701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high cardiovascular risk, the effect of liraglutide on MACE was similar in patients with and without severe hypoglycaemia (P-interaction = 0.90).
In plain wordsIn adults with type 2 diabetes, liraglutide's effect on major heart events was similar with or without severe low blood sugar.
Peptide
Liraglutide
Outcome
No significant changeEffect of liraglutide on MACE by severe hypoglycaemia status
Study
n = 9,340
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 3.5-5 yearsAs given in this study (human).
Measurements
P-interaction
0.9 P
MACE by hypoglycaemia status
Source sentences
Summary
The impact of liraglutide on risk of MACE was similar in patients with and without severe hypoglycemia (P-interaction = 0.90).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with type 2 diabetes and high risk for CV disease (n = 9,340) were randomized 1:1 to liraglutide or placebo, both in addition to standard treatment, and followed for 3.5-5 years.
Report a problemFND-2990384702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.